Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: Long-term implications

Alfonso Quintás-Cardama, Jorgé E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) depends on the kinase activity of the BCR-ABL1 fusion protein. This dependency has led to the development of BCR-ABL1 inhibitors, such as imatinib, dasatinib, and nilotinib, which have proved to be highly efficacious treatments for CML. The European LeukemiaNet guidelines have established the importance of achieving a certain depth of response at different time points during imatinib therapy for patients with newly diagnosed CML in chronic phase. Patients who achieve a complete cytogenetic response by 12 months or a major molecular response by 18 months are classified as optimal responders and deemed to have excellent long-term outcomes. Conversely, failing to achieve such milestones is associated with an increased risk of worse long-term outcomes, such as loss of response, disease progression, or death. With ongoing treatment, patients not in complete cytogenetic response face a decreasing probability of ever achieving a complete cytogenetic response or major molecular response and increasing risk of disease progression. Available data therefore support treatment recommendations based on achieving defined levels of response within a specified duration of treatment. Recent data have shown that dasatinib and nilotinib used as frontline CML therapy result in higher response rates that are achieved at earlier time points compared with standard-dose imatinib therapy. Future analyses will need to determine whether these higher rates of deep and fast responses translate into improved long-term survival. Cancer 2011;. © 2011 American Cancer Society. In patients with chronic myeloid leukemia in chronic phase, several studies have shown that early response to imatinib is associated with optimal long-term outcomes. These findings highlight the significance of emerging data from randomized trials showing that compared with imatinib, both dasatinib and nilotinib are associated with higher response rates at early time points and more rapid responses.

Original languageEnglish (US)
Pages (from-to)5261-5270
Number of pages10
JournalCancer
Volume117
Issue number23
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Disease Progression
Phosphotransferases
Imatinib Mesylate
Guidelines
Survival

Keywords

  • BCR-ABL1
  • chronic myeloid leukemia
  • dasatinib
  • early response
  • imatinib
  • molecular response
  • nilotinib
  • polymerase chain reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase : Long-term implications. / Quintás-Cardama, Alfonso; Cortes, Jorgé E.; Kantarjian, Hagop M.

In: Cancer, Vol. 117, No. 23, 01.12.2011, p. 5261-5270.

Research output: Contribution to journalReview article

@article{791c104fc02241f18ea17c4364046f8e,
title = "Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: Long-term implications",
abstract = "Chronic myeloid leukemia (CML) depends on the kinase activity of the BCR-ABL1 fusion protein. This dependency has led to the development of BCR-ABL1 inhibitors, such as imatinib, dasatinib, and nilotinib, which have proved to be highly efficacious treatments for CML. The European LeukemiaNet guidelines have established the importance of achieving a certain depth of response at different time points during imatinib therapy for patients with newly diagnosed CML in chronic phase. Patients who achieve a complete cytogenetic response by 12 months or a major molecular response by 18 months are classified as optimal responders and deemed to have excellent long-term outcomes. Conversely, failing to achieve such milestones is associated with an increased risk of worse long-term outcomes, such as loss of response, disease progression, or death. With ongoing treatment, patients not in complete cytogenetic response face a decreasing probability of ever achieving a complete cytogenetic response or major molecular response and increasing risk of disease progression. Available data therefore support treatment recommendations based on achieving defined levels of response within a specified duration of treatment. Recent data have shown that dasatinib and nilotinib used as frontline CML therapy result in higher response rates that are achieved at earlier time points compared with standard-dose imatinib therapy. Future analyses will need to determine whether these higher rates of deep and fast responses translate into improved long-term survival. Cancer 2011;. {\circledC} 2011 American Cancer Society. In patients with chronic myeloid leukemia in chronic phase, several studies have shown that early response to imatinib is associated with optimal long-term outcomes. These findings highlight the significance of emerging data from randomized trials showing that compared with imatinib, both dasatinib and nilotinib are associated with higher response rates at early time points and more rapid responses.",
keywords = "BCR-ABL1, chronic myeloid leukemia, dasatinib, early response, imatinib, molecular response, nilotinib, polymerase chain reaction",
author = "Alfonso Quint{\'a}s-Cardama and Cortes, {Jorg{\'e} E.} and Kantarjian, {Hagop M.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1002/cncr.26196",
language = "English (US)",
volume = "117",
pages = "5261--5270",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase

T2 - Long-term implications

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorgé E.

AU - Kantarjian, Hagop M.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Chronic myeloid leukemia (CML) depends on the kinase activity of the BCR-ABL1 fusion protein. This dependency has led to the development of BCR-ABL1 inhibitors, such as imatinib, dasatinib, and nilotinib, which have proved to be highly efficacious treatments for CML. The European LeukemiaNet guidelines have established the importance of achieving a certain depth of response at different time points during imatinib therapy for patients with newly diagnosed CML in chronic phase. Patients who achieve a complete cytogenetic response by 12 months or a major molecular response by 18 months are classified as optimal responders and deemed to have excellent long-term outcomes. Conversely, failing to achieve such milestones is associated with an increased risk of worse long-term outcomes, such as loss of response, disease progression, or death. With ongoing treatment, patients not in complete cytogenetic response face a decreasing probability of ever achieving a complete cytogenetic response or major molecular response and increasing risk of disease progression. Available data therefore support treatment recommendations based on achieving defined levels of response within a specified duration of treatment. Recent data have shown that dasatinib and nilotinib used as frontline CML therapy result in higher response rates that are achieved at earlier time points compared with standard-dose imatinib therapy. Future analyses will need to determine whether these higher rates of deep and fast responses translate into improved long-term survival. Cancer 2011;. © 2011 American Cancer Society. In patients with chronic myeloid leukemia in chronic phase, several studies have shown that early response to imatinib is associated with optimal long-term outcomes. These findings highlight the significance of emerging data from randomized trials showing that compared with imatinib, both dasatinib and nilotinib are associated with higher response rates at early time points and more rapid responses.

AB - Chronic myeloid leukemia (CML) depends on the kinase activity of the BCR-ABL1 fusion protein. This dependency has led to the development of BCR-ABL1 inhibitors, such as imatinib, dasatinib, and nilotinib, which have proved to be highly efficacious treatments for CML. The European LeukemiaNet guidelines have established the importance of achieving a certain depth of response at different time points during imatinib therapy for patients with newly diagnosed CML in chronic phase. Patients who achieve a complete cytogenetic response by 12 months or a major molecular response by 18 months are classified as optimal responders and deemed to have excellent long-term outcomes. Conversely, failing to achieve such milestones is associated with an increased risk of worse long-term outcomes, such as loss of response, disease progression, or death. With ongoing treatment, patients not in complete cytogenetic response face a decreasing probability of ever achieving a complete cytogenetic response or major molecular response and increasing risk of disease progression. Available data therefore support treatment recommendations based on achieving defined levels of response within a specified duration of treatment. Recent data have shown that dasatinib and nilotinib used as frontline CML therapy result in higher response rates that are achieved at earlier time points compared with standard-dose imatinib therapy. Future analyses will need to determine whether these higher rates of deep and fast responses translate into improved long-term survival. Cancer 2011;. © 2011 American Cancer Society. In patients with chronic myeloid leukemia in chronic phase, several studies have shown that early response to imatinib is associated with optimal long-term outcomes. These findings highlight the significance of emerging data from randomized trials showing that compared with imatinib, both dasatinib and nilotinib are associated with higher response rates at early time points and more rapid responses.

KW - BCR-ABL1

KW - chronic myeloid leukemia

KW - dasatinib

KW - early response

KW - imatinib

KW - molecular response

KW - nilotinib

KW - polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=81755161540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755161540&partnerID=8YFLogxK

U2 - 10.1002/cncr.26196

DO - 10.1002/cncr.26196

M3 - Review article

C2 - 21598241

AN - SCOPUS:81755161540

VL - 117

SP - 5261

EP - 5270

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -